Differential effects of terlipressin on pulmonary and systemic hemodynamics in patients with cirrhosis and pulmonary hypertension: An echo study

Angiology

Volumn 63, Issue 3, 2012, Pages 199-205

  Kalambokis, Georgios N ^a   Pappas, Konstantinos ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

cirrhosis; pulmonary hypertension; terlipressin

Indexed keywords

TERLIPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOGRAPHY; DRUG EFFECT; FEMALE; HEART OUTPUT; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS, ALCOHOLIC; LYPRESSIN; MALE; MIDDLE AGED; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR RESISTANCE;

EID: 84857860766     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711411704     Document Type: Article

References (42)

1. Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis. 2006 ; 26 (3). 265-272 (Pubitemid 44141934)
2. Golbin JM, Krowka MJ.. Portopulmonary hypertension. Clin Chest Med. 2007 ; 28 (1). 203-218 (Pubitemid 46330545)
3. Hoeper MM, Krowka MJ, Strassburg CP.. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004 ; 363 (suppl 3). 1461-1468 (Pubitemid 38586724)
4. Kalambokis G, Mouzaki A, Rodi M, Pappas K, Korantzopoulos P, Tsianos EV.. Serum interleukin 6 levels and cirrhosis-associated pulmonary hypertension. Angiology. 2011 ; 62 (4). 344-345
5. Cotton CL, Gandhi S, Vaitkus PT, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl. 2002 ; 8 (11). 1051-1054 (Pubitemid 35363632)
6. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000 ; 6 (4). 453-458 (Pubitemid 30489119)
7. Scapellato F, Temporelli PL, Eleuteri E, Corra U, Imparato A, Giannuzzi P.. Accurate noninvasive estimation of pulmonary vascular resistance by Doppler echocardiography in patients with chronic heart failure. J Am Coll Cardiol. 2001 ; 37 (7). 1813-1819 (Pubitemid 32499964)
8. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ.. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol. 2003 ; 41 (6). 1021-1027 (Pubitemid 36315548)
9. Farzaneh-Far R, McKeown BH, Dang D, Roberts J, Schiller NB, Foster E.. Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation. Am J Cardiol. 2008 ; 101 (2). 259-262
10. Wong F, Moore K, Dingemanse J, Jalan R.. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2007 ; 47 (1). 160-168 (Pubitemid 351171053)
11. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD.. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol. 2006 ; 41 (6). 593-597
12. Saner FH, Canbay A, Gerken G, Broelsch CE.. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 ; 1 (2). 207-217
13. Krag A, Borup T, Møller S, Bendtsen F.. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther. 2008 ; 25 (11). 1105-1140
14. Altintas E, Akkus N, Gen R, Helvaci MR, Sezgin O, Oguz D.. Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis. World J Gastroenterol. 2004 ; 10 (15). 2278-2280 (Pubitemid 39144984)
15. Kalambokis G, Korantzopoulos P, Nikas SA, Theodorou A, Tsianos EV.. Significant improvement of portopulmonary hypertension after 1-week terlipressin treatment. J Hepatol. 2008 ; 48 (4). 678-680
16. Himelman RB, Stulbarg M, Kircher B, et al. Noninvasive estimation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation. 1989 ; 79 (4). 863-871 (Pubitemid 19100546)
17. Wong F, Moore K, Dingemanse J, Jalan R.. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008 ; 47 (1). 160-168 (Pubitemid 351171053)
18. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD.. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol. 2006 ; 41 (6). 593-597
19. Garcia-Tsao G.. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001 ; 120 (3). 726-748 (Pubitemid 32171643)
20. Tahara A, Tomura Y, Wada K, et al. Characterization of vasopressin receptor in rat lung. Neuropeptides. 1998 ; 32 (3). 281-286 (Pubitemid 28267150)
21. Fay MJ, Du J, Yu X, North WG.. Evidence of expression of vasopressin V2 receptor mRNA in human lung. Peptides. 1996 ; 17 (3). 477-481 (Pubitemid 26180222)
22. Chamamoro C, Silva JA, Romera MA, Marquez J, Pardo C.. Vasopressin effect on pulmonary arterial pressure. Anesth Analg. 2002 ; 94 (2). 479 (Pubitemid 34106859)
23. Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med. 2007 ; 35 (10). 2280-2285 (Pubitemid 47476224)
24. Albanese J, Leone M, Delmas A, Martin C.. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005 ; 33 (9). 1897-1902 (Pubitemid 41306507)
25. Westaby D, Gimson A, Hayes PC, Williams R.. Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension. Gut. 1988 ; 29 (3). 372-377 (Pubitemid 18082155)
26. Lin HC, Tsai YT, Lee FY, et al. Systemic and portal hemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis. J Hepatol. 1990 ; 10 (3). 370-374
27. Valla D, Lee SS, Moreau R, Hadengue A, Sayegh R, Lebrec D.. Effects of glypressin on the splanchnic and systemic circulation in patients with cirrhosis. Gastroenterol Clin Biol. 1985 ; 9 (12). 877-880 (Pubitemid 16133400)
28. Filippi L, Gozzini E, Daniotti M, Pagliai F, Catarzi S, Fiorini P.. Rescue treatment with terlipressin in different scenarios of refractory hypotension in newborns and infants. Pediatr Crit Care Med. 2011 ; 12 (6). e237-41
29. Stathopoulos L, Nicaise C, Michel F, et al. Terlipressin as rescue therapy for refractory pulmonary hypertension in a neonate with a congenital diaphragmatic hernia. J Pediatr Surg. 2011 ; 46 (2). 19-21
30. Papoff P, Caresta E, Versacci P, Grossi R, Midulla F, Moretti C.. The role of terlipressin in the management of severe pulmonary hypertension in congenital diaphragmatic hernia. Paediatr Anaesth. 2009 ; 19 (8). 805-806
31. Price LC, Forrest P, Sodhi V, et al. Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth. 2007 ; 99 (4). 552-555 (Pubitemid 47412500)
32. Evora PRB, Pearson PJ, Schaff HV.. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor mediated production of nitric oxide. Chest. 1993 ; 103 (4). 1241-1245 (Pubitemid 23110307)
33. Russ RD, Walker BR.. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol. 1992 ; 262 (3)(Pt 2). H743 - H747
34. Walker BR, Haynes J, Wang HL, Voelkel NF.. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol. 1989 ; 257 (2)(Pt 2). H415 - H422
35. Eichinger MR, Walker BR.. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol. 1994 ; 267 (2)(Pt 2). H2413-2419
36. Schini VB, Katusic ZS, Vanhoutte PM.. Neurohypophyseal peptides and tachykinins stimulate the production of cyclic GMP in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther. 1990 ; 255 (3). 994-1000
37. Jin HK, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S.. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci. 1989 ; 298 (4). 227-236 (Pubitemid 19262397)
38. Arroyo V, Colmenero J.. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol. 2003 ; 38 (suppl 1). 69-89
39. Naeije R, Hallemans R, Mols P, Melot C, Reding P.. Effects of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. Crit Care Med. 1982 ; 10 (9). 578-582
40. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F.. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003 ; 52 (9). 1355-1362 (Pubitemid 37026471)
41. Kalambokis GN, Fotopoulos A, Pappas K, Tsianos EV.. Renal function impairment in patients with cirrhosis having pulmonary hypertension. Angiology. 2011 ; 62 (7). 585-587
42. Lin HC, Hou MC, Lee WC, et al. Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis. Am J Gastroenterol. 1999 ; 94 (4). 1012-1017